These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18223511)

  • 1. [Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)].
    Farnier M
    Arch Mal Coeur Vaiss; 2007 Dec; 100(12):985-7, 990-1. PubMed ID: 18223511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic approaches for dyslipidemias].
    Vergès B
    Soins; 2008 Apr; (724 Suppl):S21-3. PubMed ID: 18496974
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)].
    Farnier M
    Arch Mal Coeur Vaiss; 2007 Dec; 100(12):979-84. PubMed ID: 18223510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders.
    Antel J; Gregory PC; Nordheim U
    J Med Chem; 2006 Jul; 49(14):4008-16. PubMed ID: 16821760
    [No Abstract]   [Full Text] [Related]  

  • 7. Using cardiovascular age equivalent to close the treatment gap for dyslipidemia.
    Eaton CB
    Arch Intern Med; 2007 Nov; 167(21):2288. PubMed ID: 18039985
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of dyslipidaemia - evidence and practical recommendations.
    Nestel PJ; O'Brien R; Nelson M
    Aust Fam Physician; 2008 Jul; 37(7):521-7. PubMed ID: 18592069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction is difficult, particularly about the future.
    Jackson R; Wells S
    Arch Intern Med; 2007 Nov; 167(21):2286-7. PubMed ID: 18039984
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.
    Chmielewski M; Carrero JJ; Nordfors L; Lindholm B; Stenvinkel P
    J Nephrol; 2008; 21(5):635-44. PubMed ID: 18949717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and cardiometabolic syndrome in children.
    Velasquez-Mieyer P; Neira CP; Nieto R; Cowan PA
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):61-81. PubMed ID: 19124396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid management in children.
    Zappalla FR; Gidding SS
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):171-83. PubMed ID: 19217518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical review of the cannabinoid receptor as a drug target for obesity management.
    Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
    Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red mold rice prevents the development of obesity, dyslipidemia and hyperinsulinemia induced by high-fat diet.
    Chen WP; Ho BY; Lee CL; Lee CH; Pan TM
    Int J Obes (Lond); 2008 Nov; 32(11):1694-704. PubMed ID: 18794894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC; Nardi M; Da Ros S; Castellano V
    Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [AFSSAPS guideline for the treatment of dyslipidemia].
    Agence Francaise de Securite Sanitaire des Produits de Sante
    Rev Prat; 2005 Oct; 55(16):1788-93. PubMed ID: 16363429
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.